JP2024529141A - Ｈｅｒ３抗原結合性分子を使用したがんの処置および予防 - Google Patents

Ｈｅｒ３抗原結合性分子を使用したがんの処置および予防 Download PDF

Info

Publication number
JP2024529141A
JP2024529141A JP2024508570A JP2024508570A JP2024529141A JP 2024529141 A JP2024529141 A JP 2024529141A JP 2024508570 A JP2024508570 A JP 2024508570A JP 2024508570 A JP2024508570 A JP 2024508570A JP 2024529141 A JP2024529141 A JP 2024529141A
Authority
JP
Japan
Prior art keywords
her3
cancer
mutation
contain
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024508570A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024529141A5 (enExample
Inventor
ボイド－カーカップ，ジェローム・ダグラス
カー，シュレヤ
パシュキェヴィチ，コンラッド
タッカー，ディッティ
イングラム，ピアーズ
Original Assignee
ハミングバード・バイオサイエンス・プライベート・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハミングバード・バイオサイエンス・プライベート・リミテッド filed Critical ハミングバード・バイオサイエンス・プライベート・リミテッド
Publication of JP2024529141A publication Critical patent/JP2024529141A/ja
Publication of JP2024529141A5 publication Critical patent/JP2024529141A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2024508570A 2021-08-13 2022-08-12 Ｈｅｒ３抗原結合性分子を使用したがんの処置および予防 Pending JP2024529141A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163232883P 2021-08-13 2021-08-13
US63/232,883 2021-08-13
PCT/EP2022/072674 WO2023017151A1 (en) 2021-08-13 2022-08-12 Treatment and prevention of cancer using her3 antigen-binding molecules

Publications (2)

Publication Number Publication Date
JP2024529141A true JP2024529141A (ja) 2024-08-01
JP2024529141A5 JP2024529141A5 (enExample) 2025-08-20

Family

ID=83228993

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024508570A Pending JP2024529141A (ja) 2021-08-13 2022-08-12 Ｈｅｒ３抗原結合性分子を使用したがんの処置および予防

Country Status (6)

Country Link
US (1) US20250136712A1 (enExample)
EP (1) EP4384640A1 (enExample)
JP (1) JP2024529141A (enExample)
KR (1) KR20240045281A (enExample)
CN (1) CN118119719A (enExample)
WO (1) WO2023017151A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4687972A1 (en) 2023-04-06 2026-02-11 Hummingbird Bioscience Pte. Ltd. Treatment and prevention of cancer using her3 antigen-binding molecules
WO2025056781A1 (en) * 2023-09-15 2025-03-20 Hummingbird Bioscience Pte. Ltd. Treatment and prevention of cancer using her3-binding molecules

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140222443A1 (en) * 2011-06-07 2014-08-07 Kathleen Danenberg Molecular profiling for cancer
JP2020533269A (ja) * 2016-12-14 2020-11-19 デベロップメント センター フォー バイオテクノロジー 抗体−薬物複合体およびその使用
WO2019185164A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Holdings Pte. Ltd. Her3 antigen-binding molecules
GB201913079D0 (en) 2019-09-11 2019-10-23 Hummingbird Bioscience Holdings Pte Ltd Treatment and prevention of cancer using her3 antigen-binding molecules

Also Published As

Publication number Publication date
WO2023017151A9 (en) 2024-06-06
WO2023017151A1 (en) 2023-02-16
EP4384640A1 (en) 2024-06-19
CN118119719A (zh) 2024-05-31
US20250136712A1 (en) 2025-05-01
KR20240045281A (ko) 2024-04-05

Similar Documents

Publication Publication Date Title
JP2023103258A (ja) がんの治療法及び診断法
TWI775781B (zh) 癌症之治療性及診斷性方法
JP2022172083A (ja) 癌のための治療方法及び診断方法
JP6449308B2 (ja) がんバイオマーカー及びその使用
JP2024119815A (ja) 腫瘍を処置する方法
JP2025081454A (ja) 腫瘍を処置する方法において使用するための抗ｐｄ－１抗体
JP2024167282A (ja) 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ－１抗体
JP2021502066A (ja) がんの診断及び療法
TW201837467A (zh) 用於癌症之診斷及治療方法
KR20130103734A (ko) 바이오마커 및 치료 방법
JP2018534927A (ja) Ｉｃｏｓ発現を決定する遺伝子シグネチャー
CN112912403A (zh) 治疗肿瘤的方法
US20240310266A1 (en) Biomarkers for cancer and methods of use thereof
US20240101707A1 (en) A method of preventing, alleviating or treating a tumor
CN113891748A (zh) 治疗肿瘤的方法
US20250136712A1 (en) Treatment and prevention of cancer using her3 antigen-binding molecules
WO2020211804A1 (zh) 抗pd-1抗体在制备治疗实体瘤的药物中的用途
US20230392210A1 (en) Methods and compositions for cancer immunotherapy
JP2023520515A (ja) がんに対する治療方法及び診断方法
TW202321309A (zh) 使用至少結合ｅｇｆｒ之抗體治療免疫檢查點抑制劑治療之具高ｅｇｆｒ表現的癌症
KR20260026009A (ko) Her3 항원 결합 분자를 이용한 암의 치료 및 예방
JP2026513904A (ja) Ｈｅｒ３抗原結合分子を使用する、がんの処置および予防
WO2025056781A1 (en) Treatment and prevention of cancer using her3-binding molecules
US20240024320A1 (en) Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody
TW202436335A (zh) 治療表現ｄｌｌ３的癌症之方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250812

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250812